ACT Brief: Lilly Seeks FDA Priority Review
Eli Lilly's orforglipron may become the first oral GLP-1 therapy reviewed under FDA's new national priority program.
Bispecific antibody research in oncology is redefining ethical standards, with the global BsAb market projected to quadruple by 2030.
Emerging Regulatory Frameworks
- Bispecific antibodies are driving immuno-oncology innovation.
- Eli Lilly is preparing to submit orforglipron to FDA's national priority review program.
The global BsAb market is projected to quadruple by 2030.
Author's summary: Lilly seeks FDA review for oral GLP-1 therapy.